anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants will receive 3 weeks of daily (Monday to Friday) rTMS sessions followed by 3 weeks of weekly rTMS sessions for a total of 6 weeks of treatment. Each session lasts about 25 minutes and is provided by an rTMS technician at the Temerty Center at 1025 Queen Street West, with medical supervision.
Treatment of patients with HIV infection must address both the primary viral infection and the subsequent immune deficiency, which is the primary cause of mortality in AIDS. In vitro studies of ampligen have shown it will inhibit HIV infection. Ampligen may also minimize the toxicity of many drugs used in the treatment of AIDS and induce an antiviral state in the brain that may be useful in treating neurologic symptoms of HIV infection. The time course and degree of immunologic response to ampligen remain unknown although they are essential for proper use of the drug in the treatment of HIV infection and perhaps other clinical problems.

Ten healthy volunteers and 10 HIV-infected patients are randomized between ampligen or placebo group. Five volunteers in each group receive a single dose of ampligen on day 1 and a single dose of placebo on day 8. The other 5 volunteers receive the drug and placebo on day 8 and 1, respectively. Seven days of observation and testing follow each administration of drug or placebo and also allow the body to eliminate the drug.
The invention relates to a flavone-metal complex microsphere which is in a spherical shape and in the structure of a solid sphere or a hollow sphere or a porous sphere, and the particle size of the sphere is 50nm-5000nm. The flavone-metal complex microsphere is formed by complexing flavonoid substances such as flavanol, anthocyanidin, tea polyphenol and the like with metal, and the preparation process comprises the following sequential steps: (1) preparing a flavone solution, (2) reacting and synthesizing, and (3) collecting and drying the product. In the reaction for synthesis, glycerin or glycol is used as an assistant, and the reaction temperature is 60 DEG C-70 DEG C for obtaining the solid microsphere. In the reaction for synthesis, ethyl acetate or vinyl alcohol is used as an assistant, and the reaction temperature is 90 DEG C-150 DEG C for obtaining the hollow microsphere. In the reaction for synthesis, ethanol is used as an assistant, and the reaction temperature is 70 DEG C-90 DEG C for obtaining the porous microsphere. The flavone-metal complex hollow microsphere can be used as a drug carrier or fluorescence molecular carrier for application.
Non-Interventional. Patients with advanced melanoma treated with nivolumab monotherapy prescribed as first-line therapy between June 2015 and June 2016.
The present invention relates to a novel engineered receptor CD4 which is designated CD4-GP41c and, when expressed with CXCR4 or CCR5 at the surface of a gene therapy retrovirus allows a more efficient and specific infection of HIV infected cells than CD4. The present invention also relates to a method of producing said novel retrovirus vectors. The present invention also relates to recombinant viruses expressing membrane proteins CD4-GP41c or CD4-GP41c/DC-SIGNs, or expressing membrane proteins CD4/DC-SIGN, with either one of its co-receptors CXCR4 or CCR5 allowing the delivery of a gene of interest, for targeting and delivering said gene of interest specifically to virus-infected cells, particularly HIV+ infected cell, and thereby triggering cell death. The recombinant virus according to the present invention is particular useful as a gene therapy vector, as it confers efficient and specific gene transfer to virus-infected cells, such as HIV- infected T helper cells and macrophages. The present invention also relates to a general method of producing novel enveloped viral system which allow to deliver of a a gene of interest to a target cell. The present invention also concerns the use of a protein DC-SIGNs at the surface of an enveloped viral system such as a retrovirus, particularly HIV, for improving the infectivity and/or the titer of said enveloped viral system. The present invention further relates to the use of such envelope system of the present invention for the preparation of a pharmaceutical composition for the treatment of virus infection or pathologies induced by viral infection, particularly HIV infection.
The purpose of this research is to study how testosterone affects blood pressure control in trans men. High testosterone levels are detrimental to the female cardiovascular system in that higher levels are associated with increased blood pressure. Humans control blood pressure in the autonomic nervous system via the baroreflex mechanism. The arterial baroreflex is a key autonomic homeostatic mechanism involved in maintaining arterial blood pressure, and gain of the baroreflex is used as a measure of the sensitivity of sympathetic responses that act to restore acute blood pressure fluctuations. This autonomic regulation of blood pressure is also characterized by rhythmic activity (changes in cardiac frequency), which can be observed by recording sympathetic nerve traffic. When the female cardiovascular system is exposed to elevated androgens, baroreflex gain is impaired, and blood control is less efficient during an orthostatic challenge. However, to best understand the effect of a given stimulus on autonomic function, changes in frequency of the SNSA response must also be quantified in addition to the gain. Sympathetic control of arterial blood pressure is most effective in a narrow frequency range, and if this frequency range for responsiveness should narrow further, control of arterial blood pressure becomes less efficient and presents as dysfunction. The central hypothesis for this research is that dysregulation of blood pressure in trans men taking testosterone for gender affirming HT is a function of both reduced baroreflex gain and narrowed frequency-dependent relationship between arterial pressure and peripheral sympathetic vascular responsiveness. Specifically, these studies test the hypothesis that androgen supplementation with HT is associated with 1) lower baroreflex gain during a lower body negative pressure (LBNP) challenge, and 2) a narrowed response frequency range that precedes impaired sympathetic vascular response dynamics in trans men compared to control cisgender women.

Study procedures include an oral glucose tolerance test (OGTT), microneurography of the median nerve in the forearm to assess SNSA, and 2 LBNP challenges designed to examine baroreflex gain during static LBNP and then the frequency of SNSA during oscillating LBNP (OLBNP). Participants complete 3 visits for this study. Visit 1 is for informed consent procedures; Visit 2 is a pre-screening visit to complete the OGTT; Visit 3 is for experimental testing to assess gain and the frequency range. Blood pressure, heart rate and muscle SNSA (MSNA) are measured during LBNP and OLBNP. MSNA is recorded using 2 microelectrodes inserted through the skin of the forearm to record activity (firing) of the median nerve. Blood samples are taken via IV placement to measure insulin and glucose during the OGTT for Visit 2, and then sex hormones and catecholamines during Visit 3. Results from the group of young trans men will be compared to a control group of cisgender women matched for age and body mass index.
The invention provides the application of arjunolic acid or salts thereof suitable for medical purpose in the preparation of a drug of an Alpha-glucosidase inhibitor. The invention is characterized in that strong effective Alpha-glucosidase inhibitor is extracted and separated from lagerstroemia plants which has rich source, are easy to be extracted and can be recycled for a plurality of times, thus not only promoting economic benefit, but also being environment-friendly. Furthermore, the monomeric compound product of the Alpha-glucosidase inhibitor is stable and is convenient to be stored. Pharmacological tests prove that the arjunolic acid has powerful effect in inhibiting Alpha-glucosidase, wherein, physiological change or diseases caused by or related to the Alpha-glucosidase includes but is not limited to Type II Diabetes. The monomeric compound product of the Alpha-glucosidase inhibitor can be further developed into the drugs for clinically treating NIDDM, thereby having better prospect for marketization. The constitutional formula of compound of the arjunolic acid is shown as above.
Infectious causes of diarrhea contribute significantly to morbidity in Asia. We conducted a systematic review and meta-analysis of the prevalence of infectious etiologies of persistent and chronic diarrhea in Asian adults. Searches were performed on PubMed and Scopus for studies from January 1, 1970, to May 30, 2023. Sixteen studies were identified and included. The meta-analysis was conducted with the random-effects method, estimating the pooled prevalence of groups of infectious pathogens as causes of persistent and chronic diarrhea among Asian adults. The findings were highly heterogeneous and indicative of publication bias. The majority of studies were conducted on persons living with human immunodeficiency virus infection (PLHIV). The studies were predominantly from low-income and middle-income Asian countries. The most common cause was parasitic, with a pooled prevalence of 0.52 (95% confidence interval 0.28-0.65, I2 = 99%, Cochran's Q = 1027.44, P < 0.01), followed by bacterial, fungal, and viral causes, which were substantially rarer. Negative microbiological testing was also common, with a pooled prevalence for a negative test being 0.37 (95% confidence interval 0.17-0.52, I2 = 99%, Cochran's Q = 1027.44, P < 0.01). Subgroup analyses of studies conducted among PLHIV, from year 2000 and among those conducted in Southeast Asia showed a similar prevalence of parasitic causes of diarrhea. In conclusion, in Asian adults with persistent and chronic diarrhea, parasitic causes were most prevalent. However, the estimate of true prevalence is limited by significant heterogeneity among the available studies. More study in this field is required, especially examining PLHIV in the post-antiretroviral therapy era and from high-income countries.
Akkermansia muciniphila, which comprises one or both among AM06 and AM02. AM06 is Akkermansia muciniphila with an accession number of CGMCC No. 22793, and AM02 is Akkermansia muciniphila with an accession number of CGMCC No. 22794. It has been proven by experimentation that viable bacteria, inactivated bacteria and bacterial lysates of Akkermansia muciniphila have the effect of preventing and treating tumors. Disclosed are an Akkermansia muciniphila product for preventing and treating tumors and a use thereof. Same at least comprises Akkermansia muciniphila and may further comprise an immune checkpoint inhibitor, such as a PD-1 antibody, a CTLA-4 antibody, and the like. When Akkermansia muciniphila is used in combination with the immune checkpoint inhibitor, Akkermansia muciniphila can significantly enhance the anti-tumor effect of the immune checkpoint inhibitor.
This study aims to advance our therapeutic armamentarium by evaluating the efficacy of estradiol (E2) therapy for Postpartum Major Depression (PPMD), which has received minimal research attention in America. The design of the proposed study is an 8 week randomized double-blind clinical trial of SERT vs. E2 vs. Placebo. Responders enter a continuation phase with the blind intact through 6.5 months postpartum. The primary aims of this investigation are to: 1) Test the efficacy of E2 compared to placebo for the treatment of PPMD. Sertraline will be included as an active comparator. We have powered the study to test for differences among the three groups and also test for differences between the E2 and placebo group. We will test the hypothesis that E2 will be significantly more effective than placebo and that SERT will be significantly more effective than placebo. 2) Evaluate developmental outcomes in infants exposed to the disorder, PPMD, and the medications (SERT, exogenous E2 or Placebo) which may be transmitted to the infants through breastfeeding. All infants in this study will have exposure to mothers with depression. We will assess maternal depression, mother-infant serum SERT and E2 levels and relate them to mother-infant interactional quality and infant developmental outcomes on the Bayley Scales of Infant Development. These data will enhance the sophistication of risk-benefit analyses for pharmacotherapy during lactation.
Fosinopril and fosinoprilat inhibit angiotensin-converting enzyme (ACE) in human subjects and in animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion. The latter decrease may result in a small increase of serum potassium. Hypertensive patients treated with fosinopril alone for an average of 8 weeks had elevations of serum potassium of approximately 0.1 mEq/L. Similar patients treated with hydrochlorothiazide alone had a mean reduction in serum potassium of 0.15 mEq/L, while patients who received combined treatment with 10/12.5 mg or 20/12.5 mg of fosinopril and hydrochlorothiazide had reductions of 0.07 and 0.03 mEq/L, respectively. (See PRECAUTIONS.)

Removal of angiotensin II negative feedback on renin secretion leads to increased plasma renin activity.

ACE is identical to kininase, an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent vasodepressor peptide, play a role in the therapeutic effects of fosinopril sodium and hydrochlorothiazide tablets remains to be elucidated.

While the mechanism through which fosinopril lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, fosinopril has an antihypertensive effect even in patients with low-renin hypertension.

Hydrochlorothiazide is a thiazide diuretic. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts. Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium. The renin-aldosterone link is mediated by angiotensin, so coadministration of an ACE inhibitor tends to reverse the potassium loss associated with these diuretics.

The mechanism of the antihypertensive effect of thiazides is unknown.
<P>PROBLEM TO BE SOLVED: To provide a plastering material base cloth being excellent in the fitness to the body, free of emission of a poisonous gas in the incineration after the use and relatively inexpensive, and a plasting material using the same.  <P>SOLUTION: An elastic film is constituted of a composition which contains 0-25 wt.% of an olefin copolymer component (A) being a copolymer of ethylene and a 3-10C α-olefin and 100-75 wt.% of a thermoplastic elastomer component (B) being at least one kind selected from a crystalline olefin-ethylene butylene-crystalline olefin block copolymer, a 1-butene-α-olefin copolymer and an elastomeric polypropylene. The permanent elongation of the film measured according to JIS K 6301 is 50% or below. The plastering material base cloth is constituted of a composite elastic film prepared by laying an elastic nonwoven fabric on at least one surface of the elastic film. The plastering material uses the same.  <P>COPYRIGHT: (C)2004,JPO
The association between cooking fuel and hearing loss still needs more research to clarify, and two longitudinal cohort studies were explored to find if solid fuel use for cooking affected hearing in Chinese adults. The data from Chinese Health and Retirement Longitudinal Survey (CHARLS) and Chinese Longitudinal Healthy Longevity Survey (CLHLS) were analyzed. Participants (older than 18) without hearing loss at baseline and follow-up visits were included, which were divided into clean fuel and solid fuel groups. Hearing loss rate was from follow-up visits (both in year 2011) until the recent one (year 2018 in CHARLS and 2019 in CLHLS). Cox regressions were applied to examine the associations with adjustment for potential confounders. Fixed-effect meta-analysis was used to pool the results. A total of 9049 participants (average age 8.34 ± 9.12 [mean ± SD] years; 4247 [46.93%] males) were included in CHARLS cohort study and 2265 participants (average age, 78.75 ± 9.23 [mean ± SD] years; 1148 [49.32%] males) in CLHLS cohort study. There were 1518 (16.78%) participants in CHARLS cohort and 451 (19.91%) participants in CLHLS cohort who developed hearing loss. The group of using solid fuel for cooking had a higher risk of hearing loss (CHARLS: HR, 1.16; 95% CI 1.03-1.30; CLHLS: HR, 1.43; 95% CI 1.11-1.84) compared with the one of using clean fuel. Pooled hazard ratio showed the incidence of hearing loss in the solid fuel users was 1.17 (1.03, 1.29) times higher than that of clean fuel users. Hearing loss was associated with solid fuel use and older people were at higher risk. It is advised to replace solid fuel by clean fuel that may promote health equity.
The present invention relates to a raditional Chinese medicine composition for treating postpartum abdominal pain, which takes more than 10 traditional Chinese medicines of motherwort herb, prepared frankincense, prepared east Asian tree fern rhizome, raw cattail pollen etc. as the raw materials. The invention has the effects of activating blood circulation, removing blood stasis, dredging collaterals and stopping pain. Based on the differential treatment of the traditional Chinese medicine, the invention is developed by combining the latest scientific research results with the traditional Chinese medicine. The present invention aims at providing the traditional Chinese medicine composition for treating postpartum abdominal pain. The present invention is characterized by accurate efficacy, safety, convenience, no toxicity or side effects and low price.
This investigation is a single site, randomized, blinded, sham controlled, parallel group study to identify whether EA is a beneficial anesthesia adjunct in children undergoing procedures on their congenital heart defects.

Study subjects age's birth to eighteen years, undergoing cardiac surgery for their congenital heart lesions will be considered for entrance into the study. The randomized subjects will receive either EA or sham during their surgery for CHD. Subjects are expected to remain in the hospital 48 hours post procedure. Standard of care blood samples will be obtained pre-operative and post-operative. The only study specific blood sample will be Troponin I levels which will be obtained before surgery begins after the IV lines have been placed, and 6 hours after bypass. Urine samples will be obtained before surgery after placement of the foley catheter and every 6 hours post bypass aortic cross clamp removal for 48 hours while the foley catheter is still in place.
Twelve subjects will participate in 3 periods of part A, receiving 18 MIU biosimilar interferon beta-1a with albumin as i.v. bolus into a distal port under constant saline infusion as 3 treatments.
The MINT intervention will consist of 4 to 7 telephone encounters between a nurse trained in Motivational interviewing and a minority subject who recently received a coronary stent. All subjects in the MINT arm will be contacted every 3 months to complete 4 encounters. MINT is a well-known, scientifically tested behavioral counseling strategy developed as an amalgamation of principles drawn from several theoretical paradigms, the most important of which are Self-Determination Theory, Patient-Centeredness, Self-Efficacy theory, and the Stages of Change model.
Previous studies have shown that topiramate is effective in preventing migraine headaches. This is a 6-month observational study to evaluate additional safety data of topiramate in the prevention of migraine in adult patients. The study duration is 6-months, with 5 study visits during the study. Administration of topiramate should be according to current Summary of Product Characteristics (SmPC) and daily clinical practice. The decision to prescribe topiramate is decided by the Health Care Professional and it is independent of the protocol. Based on the investigator's judgement, patients who enter the study should fulfill the criteria for administration of prophylactic treatment. In this study a total number of 80 patients with diagnosed migraine according to the criteria of the International Headache Society HIS (Cephalalgia 1998; 8 (Suppl7) :1-98) will participate. Patients who will be enrolled should be either male or female over 18 years of age, fulfilling the above mentioned criteria and who will agree to sign the written informed consent for the anonymous and confidential use of their medical data with their participation in the study. Methods of evaluation include tolerability, laboratory tests, vital signs and Body Weight and Body Mass Index (BMI). Efficacy by assessing migraine attacks, symptomatic medications and Headache Impact Test (HIT-6). Observational study - No investigational drug administered.
PURPOSE:To obtain a PG-based treating agent for diseases in the hepatic and biliary tract system, containing 16,16-difluoro-15-keto-PGs as an active ingredient and having no or extremely rare side effects such as diarrhea. CONSTITUTION:This treating agent contains a compound of the formula [A is COOH, etc.; B is CH2-CH2 or CH=CH; X is H or OH; R1 is a bivalent 6C aliphatic hydrocarbon residue; R2 to R5 are each H, methyl, ethyl, etc.; Q is a single bond or a 1-6C aliphatic hydrocarbon; (m) is 0 or 1] as an active ingredient. 13,14-Dihydro-15-keto 16,16-difluoro-19-methyl-PGE is exemplified as the compound of the formula. The PG derivative is capable of manifesting improving actions on hepatopathy comparable to those of a conventional compound having a straight omega-chain. The treating agent is useful for treating fulminant hepatitis, fatty liver, hepatic coma, various acute and chronic hepatitises, hepatolenticular degeneration, hepatic hypertrophy, portal hypertension, obstructive jaundice, hepatic abscess, cirrhosis, hepatoma, cholecystitis, cholelithiasis, biliary colic, fat hypersensitivity, etc.
BACKGROUND: Two-stage exchange is a frequently performed procedure in patients who have a periprosthetic joint infection. Positive cultures when performing the second stage are perceived as a risk factor for reinfection. This study aimed to determine the impact of positive cultures during the second stage on the outcome of patients undergoing a 2-stage septic exchange and the impact of stopping the antibiotic treatment before reimplantation.
METHODS: We systematically searched four databases. We performed a meta-analysis on the risk of complications after positive cultures during second stage and a subgroup analysis by antibiotic holiday period. We included 24 studies.
RESULTS: Failure in the positive group was 37.0% and in the negative group was 13.7% with an odds ratio (OR) of 4.05. In the subgroup analysis by antibiotic holidays, failure rate without holidays was 15% and with holidays was 17.3% (P = .21). Failure in each group was higher when cultures were positive (without holidays, 25 versus 12.2%, P = .0003, and with holidays 41.1 versus 12.7%, P < .0001), but the risk of failure when cultures were positive was higher in the holiday group (OR 4.798) than in the nonholiday group (OR 2.225) in comparison to those patients who were culture negative at the second stage.
CONCLUSIONS: Microbiological eradication at second stage was not obtained in 18% of cases and it was associated with a higher failure rate. In patients with positive cultures, withholding antibiotic treatment was associated with lower failure rate. Further studies to define the antibiotic strategy in 2-stage exchange procedure are necessary.